Scott C. Chin

Scott C. Chin

Auto-generated profile, based on publicly available information

Scott C. Chin

Department of Radiation Oncology, University of Kansas Cancer Center , Kansas City, Kansas

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 February 2024 in The Journal of Immunology
Verified
Journal Article
Closed access
PDF file
MCMandy I Cheng
Mandy I Cheng
LHLee Hong
Lee Hong
CBChristian Bustillos
Christian Bustillos
BCBryan Chen
Bryan Chen
SCScott Chin
Scott Chin
MSMaureen A Su
Maureen A Su
Hypoxia is a hallmark of inflammatory conditions (e.g., inflammatory bowel disease [IBD]), and adaptive responses have consequently evolved to protect against hypoxia-associated tissue injury. Because augmenting hypoxia-induced protective responses is a promising therapeutic approach for IBD, a more complete understanding of these pathways is needed. Recent work has demonstrated that the histone demethylase UTX is oxygen-sensitive, but its role in IBD is unclear. In this study, we show that hypoxia-induced deactivation of UTX downregulates T cell responses in mucosal inflammation. Hypoxia results in decreased T cell proinflammatory cytokine production and increased immunosuppressive regulatory T cells, and these findings are recapitulated by UTX deficiency. Hypoxia leads to T cell accumulation of H3K27me3 histone modifications, suggesting that hypoxia impairs UTX’s histone demethylase activity to dampen T cell colitogenic activity. Finally, T cell–specific UTX deletion ameliorates colonic inflammation in an IBD mouse model, implicating UTX’s oxygen-sensitive demethylase activity in counteracting hypoxic inflammation.

22 April 2022 in bioRxiv
Verified
Preprint
Open access
PDF file
MCMandy I. Cheng
Mandy I. Cheng
LRLuke Riggan
Luke Riggan
JLJoey H. Li
Joey H. Li
RTRana Yakhshi Tafti
Rana Yakhshi Tafti
SCScott Chin
Scott Chin
MSMaureen A. Su
Maureen A. Su
Viral infection outcomes are sex-biased, with males generally more susceptible than females. Paradoxically, the numbers of anti-viral natural killer (NK) cells are increased in males compared to females. Using samples from mice and humans, we demonstrate that while numbers of male NK cells are increased compared to females, they display impaired production of the anti-viral cytokine IFN-γ. These sex differences were not due solely to divergent levels of gonadal hormones, since these differences persisted in gonadectomized mice. Instead, these differences can be attributed to lower male expression of X-linked Kdm6a (UTX), an epigenetic regulator which escapes X inactivation in female NK cells. NK cell-specific UTX deletion in females phenocopied multiple features of male NK cells, which include increased numbers and reduced IFN-γ production. Integrative ATAC-seq and RNA-seq analysis revealed a critical role for UTX in the regulation of chromatin accessibility and gene expression at loci important in NK cell homeostasis and effector function. Consequently, NK cell-intrinsic UTX levels are critical for optimal anti-viral immunity, since mice with NK cell-intrinsic UTX deficiency show increased lethality to mouse cytomegalovirus (MCMV) challenge. Taken together, these data implicate UTX as a critical molecular determinant of NK cell sex differences and suggest enhancing UTX function as a new strategy to boost endogenous NK cell anti-viral responses.

5 March 2026 in Cancer Discovery
Verified
Journal Article
Closed access
PDF file
JDJie Deng
Jie Deng
APAastha Pal
Aastha Pal
STStefano Testa
Stefano Testa
JXJingyu W. Xu
Jingyu W. Xu
LTLinh M. Tran
Linh M. Tran
AKAnusha Kalbasi
Anusha Kalbasi
Neoadjuvant immune checkpoint blockade (ICB) and radiotherapy (RT) improve disease-free survival in select patients with soft-tissue sarcoma (STS). However, most STS are myeloid-rich and lack preexisting T cells associated with ICB response. In preclinical models, we observed that intratumoral BO-112 [nanoplexed polyinosinic: polycytidylic acid (poly I:C)] engages myeloid cells that persist after RT, ultimately enhancing T cell–dependent tumor control. We evaluated BO-112 and hypofractionated RT, with or without nivolumab, in 14 patients with high-risk STS in a phase I neoadjuvant trial. Consistent with its immunologic potency, the triple combination induced rare immune-related adverse events (myositis–myocarditis–myasthenia gravis spectrum), mitigated by BO-112 and nivolumab dose adjustment. BO-112 and RT reprogrammed tumor-associated myeloid cells toward antigen-presenting states, promoted clonal replacement by less exhausted T cells, and enhanced malignant cell depletion compared with standard RT. These immunologic changes coincided with encouraging disease control in a small, high-risk cohort, supporting further clinical development. Significance: Intratumoral BO-112 and hypofractionated RT activate systemic T-cell immunity in mouse models and in a phase I neoadjuvant study of high-risk, resectable sarcoma. Engaging myeloid cells with BO-112 represents a potent strategy with RT to replete T cell–deficient tumors and expand the benefits of neoadjuvant ICB.

1 July 2026
Verified
Other
Open access
JDJie Deng
Jie Deng
APAastha Pal
Aastha Pal
STStefano Testa
Stefano Testa
JXJingyu W. Xu
Jingyu W. Xu
LTLinh M. Tran
Linh M. Tran
AKAnusha Kalbasi
Anusha Kalbasi
Supplementary Data is an excel file with supplementary tables S1, S3, and S6-S9 compiled. Supplemental Table 1 shows complete adverse events and relatedness to BO-112 or nivolumab by cohort. Supplemental Table 3 shows overall treatment emergent adverse events. Supplemental Table 6 shows key genes for annotation of myeloid clusters in scRNA-seq. Supplemental Table 7 shows top 100 differentially expressed genes for each myeloid cluster. Supplemental Table 8 shows annotation of T cell subsets by top differentially expressed genes. Supplemental Table 9 shows representativeness of Study Participants


1 July 2026
Verified
Other
Open access
PDF file
JDJie Deng
Jie Deng
APAastha Pal
Aastha Pal
STStefano Testa
Stefano Testa
JXJingyu W. Xu
Jingyu W. Xu
LTLinh M. Tran
Linh M. Tran
AKAnusha Kalbasi
Anusha Kalbasi
Supplemental Figure S3 shows peripheral blood and serum analysis of patients in Cohort 0 with irAEs.